Activation of adenosine A2a receptor accelerates and A2a receptor antagonist reduces intermittent hypoxia induced PC12 cell injury via PKC-KATP pathway.
Adenosine
/ analogs & derivatives
Adenosine A2 Receptor Agonists
/ pharmacology
Adenosine A2 Receptor Antagonists
/ pharmacology
Adenosine Triphosphate
/ metabolism
Animals
Cell Hypoxia
/ drug effects
KATP Channels
/ metabolism
PC12 Cells
Phenethylamines
/ pharmacology
Potassium Channels
/ metabolism
Protein Kinase C
/ metabolism
Pyrimidines
/ pharmacology
Random Allocation
Rats
Receptor, Adenosine A2A
/ metabolism
Signal Transduction
Sulfonylurea Receptors
/ metabolism
Triazoles
/ pharmacology
A2a receptor
Apoptosis
Intermittent hypoxia
KATP
Kir6.2
PKC
SUR1
Journal
Brain research bulletin
ISSN: 1873-2747
Titre abrégé: Brain Res Bull
Pays: United States
ID NLM: 7605818
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
26
03
2019
revised:
19
05
2019
accepted:
21
05
2019
pubmed:
28
5
2019
medline:
25
7
2020
entrez:
27
5
2019
Statut:
ppublish
Résumé
Obstructive sleep apnea hypopnea syndrome (OSAHS) is associated with multiple system diseases. Neurocognitive dysfunction resulting from central nervous system complications has been reported, especially in children with OSAHS. Chronic intermittent hypoxia is accepted to be the major pathophysiological mechanism of OSAHS. Adenosine plays an important role in cellular function via interactions with its receptors. A2a receptor has been recognized as a factor involved in neuroprotection. However, the role of adenosine A2a receptor in intermittent hypoxia induced cellular injury is not completely understood. In this study, we aim to investigate the underlying mechanisms of A2a receptor mediated cellular damage caused by intermittent hypoxia in PC12 cells. We found that activated A2a receptor by CGS21680 decreased cellular viability, increased PKC as well as ATP-sensitive potassium channel (KATP) subunits expression Kir6.2 and SUR1. Inhibition of A2a receptor by SCH58261 increased cellular viability, suppressed PKC and SUR1 expression level, ultimately showing a protective role in PC12 cells. Moreover, we observed that CHE, which is an antagonist of PKC, downregulated Kir6.2 and SUR1 expression and increased cellular viability. Additionally, we found that A2a receptor activation induced cell injury was associated with increased Cleaved-Caspase 3 expression, which can be decreased by inhibition of A2a receptor or PKC. In conclusion, our findings indicate that A2a receptor induced KATP expression by PKC activation and plays a role in accelerating PC12 cells injury induced by intermittent hypoxia exposure via A2a-PKC-KATP signal pathway mediated apoptosis.
Identifiants
pubmed: 31129168
pii: S0361-9230(19)30167-4
doi: 10.1016/j.brainresbull.2019.05.015
pii:
doi:
Substances chimiques
5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine
0
Abcc8 protein, rat
0
Adenosine A2 Receptor Agonists
0
Adenosine A2 Receptor Antagonists
0
KATP Channels
0
Phenethylamines
0
Potassium Channels
0
Pyrimidines
0
Receptor, Adenosine A2A
0
Sulfonylurea Receptors
0
Triazoles
0
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine
120225-54-9
Adenosine Triphosphate
8L70Q75FXE
Protein Kinase C
EC 2.7.11.13
Adenosine
K72T3FS567
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
118-126Informations de copyright
Copyright © 2019. Published by Elsevier Inc.